







The evolving landscape of treating cancer-associated thrombosis (CAT): from LMWH to Direct Oral Anticoagulants (DOACs)?

20th October (Saturday), 18:30–20:00
Hall B3 – Room 20, Messe Munich, Munich, Germany

Time	Topic	Speaker
18:30	• The burden and impact of venous thromboembolism (VTE) on cancer patients' lives	 Ingrid Pabinger-Fasching Austria (Chair)
18:45	• Assessing the risk of VTE in cancer patients and its prevention	 Phil Wells Canada
19:00	• Evidence for and shortfalls of current treatments for CAT	 Andrés Muñoz Spain (Co-chair)
19:15	• Is there a role for DOACs in CAT based on what we know from pivotal VTE trials?	 Alexander (Ander) Cohen UK
19:35	• DOACs in CAT: emerging evidence from clinical trials	 Giancarlo Agnelli Italy
19:50	• Q&A	Ingrid Pabinger-Fasching Andrés Muñoz

LMWH; low-molecular-weight heparin



This Satellite Symposium is fully organised and funded by:



Bristol-Myers Squibb

